Iatrogenic Drug EventsIATRO-URGNCT07333131
Identification of Iatrogenic Drug Events Upon Admission to the Adult Emergency Departments
An observational study of Iatrogenic Drug Events, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Pharmacists working within a multidisciplinary team have a role to play in detecting the potential iatrogenic origin of a hospital admission, in order to implement measures to improve medication use appropriately and limit readmissions for medication-related iatrogenesis. Read more about this study
- Who is it for?
- Ages 66 years and older
- Conditions the study is for
- Iatrogenic Drug Events
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 9 Jul 2025to 9 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 66 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Adult patient (> 65 years old) treated in the emergency department of Hautepierre Hospital and presenting a prioritization score > 7 according to the Von Korff score
Who may be able to join
- Adult patient (> 65 years old)
- Treated in the emergency department of Hautepierre Hospital
- Presenting a prioritization score > 7 according to the Von Korff score
- Subject (and their legal representative, if applicable) not objecting to the reuse of their data for scientific research purposes.
Who cannot join
- Presence of a written objection in the patient's medical file (and/or that of their legal representative, if applicable) to the reuse of their data for scientific research purposes
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Pharmacie - Stérilisation - CHU de Strasbourg - France
Strasbourg, 67091
Julia WALTHER, PharmD, 33 3 88 12 78 18, julia.walther@chru-strasbourg.fr
Julia WALTHER, PharmD
About this study
Pharmacists working within a multidisciplinary team have a role to play in detecting the potential iatrogenic origin of a hospital admission, in order to implement measures to improve medication use appropriately and limit readmissions for medication-related iatrogenesis. The iatrogenic detection process depends on the individual involved, their experience, and any tools consulted. Indeed, detection aids have their place in this process and aim for better identification. For example, a questionnaire called AT HARM 10 was developed by a team of experienced pharmacists to identify hospitalizations related to medication-related iatrogenesis. The use of this tool has been validated for pharmacists as well as for pharmacy students: interns and fifth-year medical students.
Identifying iatrogenic drug events among patients presenting to the emergency department using the AT HARM 10 grid in order to intervene and adapt therapeutic management. This clinical pharmacy activity complements what is already included in routine care (medication review, pharmaceutical analysis, and pharmaceutical intervention to adapt treatment).
- Conditions
- Iatrogenic Drug Events
- Keywords
- Iatrogenic drug events, Pharmaceutical intervention, Medication-related iatrogenesis
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients for whom an iatrogenic event was identified
Measured: Up to 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start9 Jul 2025
- Primary completionMay 2026 (estimated)
- Study completion9 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Iatrogenic Drug EventsStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07333131
- Sponsor's protocol ID
- 9542
- Acronym
- IATRO-URG
- Status last verified
- Dec 2025
- First submitted
- 30 Dec 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Iatrogenic Drug Events Upon Admission to the Adult Emergency Departments
- ClinicalTrials.gov ID
- NCT07333131
- Acronym / sponsor ID
- IATRO-URG / 9542
- Conditions
- Iatrogenic Drug Events
- Keywords
- Iatrogenic drug events, Pharmaceutical intervention, Medication-related iatrogenesis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 9 Jul 2025 (actual)
- Primary completion
- May 2026 (estimated)
- Study completion
- 9 May 2026 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pharmacists working within a multidisciplinary team have a role to play in detecting the potential iatrogenic origin of a hospital admission, in order to implement measures to improve medication use appropriately and limit readmissions for medication-related iatrogenesis. The iatrogenic detection process depends on the individual involved, their experience, and any tools consulted. Indeed, detection aids have their place in this process and aim for better identification. For example, a questionnaire called AT HARM 10 was developed by a team of experienced pharmacists to identify hospitalizations related to medication-related iatrogenesis. The use of this tool has been validated for pharmacists as well as for pharmacy students: interns and fifth-year medical students.
Identifying iatrogenic drug events among patients presenting to the emergency department using the AT HARM 10 grid in order to intervene and adapt therapeutic management. This clinical pharmacy activity complements what is already included in routine care (medication review, pharmaceutical analysis, and pharmaceutical intervention to adapt treatment).
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 66 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Adult patient (> 65 years old) treated in the emergency department of Hautepierre Hospital and presenting a prioritization score > 7 according to the Von Korff score
Key inclusion criteria (4 listed)
- Adult patient (> 65 years old)
- Treated in the emergency department of Hautepierre Hospital
- Presenting a prioritization score > 7 according to the Von Korff score
- Subject (and their legal representative, if applicable) not objecting to the reuse of their data for scientific research purposes.
Key exclusion criteria (1 listed)
- Presence of a written objection in the patient's medical file (and/or that of their legal representative, if applicable) to the reuse of their data for scientific research purposes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of patients for whom an iatrogenic event was identified
Time frame: Up to 9 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Iatrogenic Drug Events, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julia WALTHER, PharmD (33 3 88 12 78 18, julia.walther@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients for whom an iatrogenic event was identified (time frame: Up to 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.